{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:40:25Z","timestamp":1793194825221,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004590","name":"Helse Midt-Norge","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004590","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007849","name":"Respiratory Health Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007849","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009123","name":"Norges Teknisk-Naturvitenskapelige Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009123","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001801","name":"UWA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jtho.2022.04.008","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T12:16:27Z","timestamp":1651061787000},"page":"921-930","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"title":["BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study"],"prefix":"10.1016","volume":"17","author":[{"given":"Amber","family":"Louw","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Panou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika Maria","family":"Szejniuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Meristoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siaw Ming","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y. C. Gary","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Firth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise Andersen","family":"Lynggaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azadeh Birbaneh","family":"Asghari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mogens","family":"Vyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnni","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenette","family":"Creaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oluf Dimitri","family":"R\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2022.04.008_bib1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1183\/09059180.00007014","article-title":"Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic","volume":"24","author":"R\u00f8e","year":"2015","journal-title":"Eur Respir Rev"},{"key":"10.1016\/j.jtho.2022.04.008_bib2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/00008390-200212000-00003","article-title":"Loss of p16 expression is associated wtih histological features of melanomia invasion","volume":"12","author":"Pavey","year":"2002","journal-title":"Melanoma Res"},{"key":"10.1016\/j.jtho.2022.04.008_bib3","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2022.04.008_bib4","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jtho.2016.06.020","article-title":"BRCA-1 associated protein 1 (BAP1) immunohistochemical expression as a diagnostic tool in malignancy pleural mesothelioma classification: a large retrospective study","volume":"11","author":"Righi","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.008_bib5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.008_bib6","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1158\/1055-9965.EPI-20-0083","article-title":"Mesothelioma biomarkers: a review highlighting contributions from the early detection research network","volume":"29","author":"Pass","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.jtho.2022.04.008_bib7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2022.04.008_bib8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.lungcan.2018.03.009","article-title":"Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations","volume":"119","author":"Sneddon","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.04.008_bib9","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.jtho.2022.04.008_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3390\/ht7030020","article-title":"Genomics and epigenetics of malignant mesothelioma","volume":"7","author":"Sage","year":"2018","journal-title":"High-Throughput"},{"key":"10.1016\/j.jtho.2022.04.008_bib11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1158\/2159-8290.CD-19-1220","article-title":"Biological mechanisms and clinical significance of BAP1 mutations in human cancer","volume":"10","author":"Carbone","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2022.04.008_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102091","article-title":"BAP1: not just a BRCA1-associated protein","volume":"90","author":"Louie","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2022.04.008_bib13","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.jtho.2022.04.008_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JTO.0000000000000471","article-title":"High incidence of somatic BAP1 alterations in sporadic malignant mesothelioma","volume":"10","author":"Nasu","year":"2015","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2022.04.008_bib15","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jtho.2022.04.008_bib16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.humpath.2016.09.026","article-title":"BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma","volume":"60","author":"McGregor","year":"2017","journal-title":"Hum Pathol"},{"key":"10.1016\/j.jtho.2022.04.008_bib17","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/cyt.12738","article-title":"Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions","volume":"30","author":"\u00d6nder","year":"2019","journal-title":"Cytopathology"},{"key":"10.1016\/j.jtho.2022.04.008_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/dc.23837","article-title":"Loss of BRCA-1 associated protein 1 (BAP1) expression is useful in diagnostic cytopathology of malignant mesothelioma in effusions","volume":"46","author":"Cozzi","year":"2017","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.jtho.2022.04.008_bib19","first-page":"120","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jtho.2022.04.008_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.lungcan.2014.10.017","article-title":"Prevalence of BRCA-1 associated protein 1 germline mutation in sporadic malignant pleural mesothelioma cases","volume":"87","author":"Rusch","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.04.008_bib21","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2018.78.5204","article-title":"Frequency of germline mutations in cancer susceptibility genes in malignant mesothelioma","volume":"36","author":"Panou","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.008_bib22","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2018.79.0352","article-title":"A\u00a0subset of mesotheliomas with improved survival occurring in carriers of BAP1 and other germline mutations","volume":"36","author":"Pastorino","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2022.04.008_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/carcin\/bgu227","article-title":"Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival","volume":"36","author":"Baumann","year":"2015","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jtho.2022.04.008_bib24","doi-asserted-by":"crossref","first-page":"9008","DOI":"10.1073\/pnas.1821510116","article-title":"Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy","volume":"116","author":"Hassan","year":"2019","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.jtho.2022.04.008_bib25","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.lungcan.2020.06.024","article-title":"Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: a single center experience with systematic review and meta-analysis","volume":"146","author":"Cantini","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2022.04.008_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.603223","article-title":"BAP1-altered malignant pleural mesothelioma: outcomes with chemotherapy, immune checkpoint inhibitors and poly(ADP-ribose) polymerase inhibitors","volume":"11","author":"Dudnik","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2022.04.008_bib27","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/cyt.13015","article-title":"Diagnostic utility of BAP1 for malignant pleural mesothelioma in pleural fluid specimens with atypical morphology","volume":"33","author":"Louw","year":"2022","journal-title":"Cytopathology"},{"key":"10.1016\/j.jtho.2022.04.008_bib28","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2022.04.008_bib29","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2022.04.008_bib30","doi-asserted-by":"crossref","first-page":"13432","DOI":"10.1073\/pnas.1612074113","article-title":"High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in\u00a0mesothelioma","volume":"113","author":"Yoshikawa","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2022.04.008_bib31","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/s41467-021-21798-w","article-title":"Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment","volume":"12","author":"Zhang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2022.04.008_bib32","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulated IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2022.04.008_bib33","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/nature08966","article-title":"Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB","volume":"465","author":"Scheuermann","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2022.04.008_bib34","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1073\/pnas.1309085110","article-title":"Tumor suppressor and deubiquitinase BAP1 promotes DNA double-strand break repair","volume":"111","author":"Yu","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jtho.2022.04.008_bib35","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.jtho.2022.04.008_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00016","article-title":"Role of BRCA mutations in the modulation of response to platinum therapy","volume":"8","author":"Mylavarapu","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtho.2022.04.008_bib37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/PAT.0000000000000250","article-title":"Loss of expression of BAP1 predicts longer survival in mesothelioma","volume":"47","author":"Farzin","year":"2015","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2022.04.008_bib38","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/1310478","article-title":"Malignant mesothelioma, BAP1 immunohistochemistry, and VEGFA: does BAP1 have potential for early diagnosis and assessment of prognosis","volume":"2017","author":"Pulford","year":"2017","journal-title":"Dis Markers"},{"key":"10.1016\/j.jtho.2022.04.008_bib39","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.pathol.2018.05.002","article-title":"Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications","volume":"50","author":"Forest","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.jtho.2022.04.008_bib40","first-page":"1","article-title":"Tissue-specific significance of BAP1 gene mutation in prognostic prediction and molecular taxonomy among different types of cancer","volume":"39","author":"Wang","year":"2017","journal-title":"Tumour Biol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422002106?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086422002106?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:49:36Z","timestamp":1761562176000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086422002106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1556086422002106"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2022.04.008","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2022.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}